A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary aim is to study the effects of vorinostat on cyclin E, cyclin D1 and Ki-67
expression in aerodigestive tract tumors (lung, esophagus, and head and neck). Secondary aims
are: To evaluate the concentration of vorinostat in tumor tissue and to correlate tumor
tissue distribution with the plasma level in these patients; to perform exploratory analyses
of the effects of vorinostat on the induction of apoptosis or necrosis in treated as compared
to untreated tumors and on expression of p21, p27, EGFR and phospho-EGFR in aerodigestive
tract tumors.